Suven Pharma, Divis, Syngene: Why Macquarie is betting big on Indian pharma | Markets News - Business Standard

The Indian pharmaceutical industry , especially the CRDMO segment, could be at an inflection point, believe analysts at Macquarie . Increased pharmaceutical outsourcing, coupled with regulatory tailwinds, the brokerage said, could accelerat
Read more...